AbbVie stock price forecast: $200 on the cards?
On June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults with moderate to severe ulcerative colitis. This approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis, and Crohn’s disease. Supported by robust data from two Phase 3 clinical trials, INSPIRE and COMMAND, the approval highlights Skyrizi’s potential to become a cornerstone therapy in AbbVie’s portfolio, particularly as a s...